Financial Results Announcement - Biotricity Inc. announced its financial results for the period ended September 30, 2025[5] - The press release detailing the financial results was issued on November 14, 2025[5] Company Classification - The company is not classified as an emerging growth company under the Securities Act[4] Filing Status - The financial results will not be deemed "filed" under the Securities Exchange Act of 1934[6] Report Signatory - The report was signed by Waqaas Al-Siddiq, the Chief Executive Officer of Biotricity Inc.[11]

Financial Performance - Biotricity Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.07 per share a year ago, representing an earnings surprise of +62.50% [1] - The company posted revenues of $3.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.36%, but showing an increase from $3.27 million in the same quarter last year [2] Stock Performance - Biotricity shares have increased approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.6% [3] - The current Zacks Rank for Biotricity is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, and for the current fiscal year, it is -$0.32 on revenues of $15.8 million [7] - The estimate revisions trend for Biotricity was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Biotricity operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - For the second quarter of fiscal 2026, revenue increased by 19% to $3.9 million from $3.3 million in the prior year period, reflecting strong market adoption and strategic initiatives [9] - Gross profit for the quarter totaled $3.2 million, up 29.4% from $2.5 million in the prior year period, with a gross profit percentage improvement of 660 basis points to 81.9% [9][10] - The company achieved EBITDA of $373,000 this quarter, marking the second consecutive quarter of positive EBITDA, indicating progress towards profitability [12] Business Line Data and Key Metrics Changes - Technology fees accounted for 89% of the quarter's total revenue, highlighting strong customer satisfaction and retention [9] - The next-generation cardiac monitoring device, Biocorp Pro, has seen expanded sales, contributing to the company's revenue growth and market presence [4][5] Market Data and Key Metrics Changes - Biotricity has monitored over 2 trillion heartbeats, significantly improving patient outcomes for those with atrial fibrillation, which is a primary focus for the company [8] - The company is expanding its market reach through strategic partnerships, including contracts with the VA and leading home care groups [5] Company Strategy and Development Direction - The company is focused on innovation and operational efficiency, aiming to achieve economies of scale and maintain healthy net margins similar to SaaS-like businesses [3] - Future plans include expanding the commercial team and investing profits into commercial expansion to increase market share and drive top-line growth [5][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in the next few quarters, supported by positive cash flows and improved operating results [12][13] - The growing market interest in chronic cardiac disease management reinforces the company's confidence in its market position and future growth [14] Other Important Information - Operating expenses for the second quarter were $2.9 million, a slight increase from $2.8 million in the same period last year, with strategic investments in R&D and sales force efficiency [11] - The net loss attributable to common shareholders for the quarter was $772,000, a significant reduction from $1.6 million in the prior year period [13] Q&A Session Summary - There were no questions during the Q&A session, indicating a clear communication of the company's progress and future plans [16]

Core Insights - Biotricity Inc. reported a 19% increase in revenue for Q2 FY26, reaching $3.9 million compared to $3.3 million in the same period last year, indicating strong growth in its Technology-as-a-Service (TaaS) model [7] - The company achieved a gross margin of 81.9%, up from 75.3% year-over-year, reflecting operational efficiencies and an expanding recurring revenue base [7] - Net loss improved significantly to $0.77 million, or $0.03 per share, from a net loss of $1.7 million, or $0.07 per share, marking a 53.3% reduction in losses [7] Financial Highlights - Recurring TaaS Technology Fees rose by 4.2% year-over-year to $3.5 million, constituting 88.7% of total revenue for Q2 FY26 [7] - The company maintained a strong customer retention rate, attributed to high-quality services that prioritize diagnostic accuracy and user-friendliness [7] - Biotricity is making progress in securing regulatory approvals in key international markets, including Canada, Saudi Arabia, and Argentina, which will facilitate broader distribution [7] Operational Highlights - The company is focusing on enhancing operational efficiency through proprietary AI-driven automation, which is expected to sustain margins and accelerate growth [2] - Biotricity is expanding its market presence in the U.S. by engaging with thousands of cardiologists and forming strategic alliances with major Group Purchasing Organizations (GPOs) that represent 90% of U.S. hospitals [7] - The launch of the Biocore Pro cardiac monitoring device and large-scale pilots in leading hospital networks demonstrate the company's capability to scale its technology and impact [2]

Financial Performance - Total revenue for the six months ended September 30, 2025, was $7,759,788, representing a 20% increase from $6,468,589 in the same period of 2024[10]. - Gross profit for the three months ended September 30, 2025, was $3,181,498, up 29% from $2,459,174 in the same quarter of 2024[10]. - The net loss attributable to common stockholders for the six months ended September 30, 2025, was $1,526,616, compared to a loss of $8,601,321 in the same period of 2024[10]. - The company experienced a comprehensive loss of $1,553,499 for the six months ended September 30, 2025, compared to $8,707,114 in the same period of 2024[10]. - The net loss before dividends for the period of $690,913 for the three months ended September 30, 2025, compared to a net loss of $1,362,890 for the same period in 2024, indicating a year-over-year improvement[11]. - For the six months ended September 30, 2025, Biotricity reported a net loss of $1,362,890, a significant improvement compared to a net loss of $5,256,288 for the same period in 2024, representing a reduction of approximately 74%[14]. Revenue Breakdown - Technology fees for the six months ended September 30, 2025, amounted to $6,882,846, up from $6,081,064 in 2024, reflecting a growth of 13%[28]. - Device sales increased significantly to $876,942 for the six months ended September 30, 2025, compared to $387,525 in 2024, marking a growth of 126%[28]. Assets and Liabilities - Total current assets increased to $5,536,234 as of September 30, 2025, from $4,639,292 as of March 31, 2025[8]. - Total liabilities rose to $37,984,860 as of September 30, 2025, compared to $35,655,054 as of March 31, 2025[8]. - Cash decreased to $308,460 as of September 30, 2025, from $365,145 as of March 31, 2025[8]. - The company reported a working capital deficiency of $18,077,790 as of September 30, 2025, compared to $15,996,856 as of March 31, 2025, highlighting liquidity concerns[21]. Equity and Stockholder Information - The number of common shares outstanding increased to 26,791,608 as of September 30, 2025, from 26,081,295 as of March 31, 2025[8]. - The total common shares issued increased to 26,952,280 as of September 30, 2025, up from 26,728,441 as of June 30, 2025, representing a growth of approximately 0.84%[11]. - The total stockholders' deficiency increased from $32,798,917 to $33,412,378, indicating a decline in overall equity position[11]. - The company’s accumulated deficit reached $140,968,401 as of September 30, 2025, reflecting ongoing financial challenges[11]. Cash Flow and Financing - Cash generated from operating activities was $42,241 for the six months ended September 30, 2025, a turnaround from cash used of $1,891,299 in the same period of 2024[14]. - Cash paid for interest during the six months ended September 30, 2025, was $1,683,697, compared to $1,235,256 in the same period of 2024, indicating increased financing costs[14]. - The Company issued $11,275,500 in Series A Convertible Promissory Notes, which accrue interest at 12% per annum, with a maturity date of one year from the final closing date[75]. - The Company issued Series C Notes totaling $1,812,700 with net proceeds of $1,100,430 after financing fees[104]. Stock-Based Compensation - The company recorded stock-based compensation of $6,001 for the ESOP during the period, contributing to the overall equity adjustments[11]. - Stock-based compensation under the ESOP was recorded at $115,863, reflecting the company's commitment to employee incentives[13]. - The Company recognized stock-based compensation of $6,001 and $11,936 for the three and six months ended September 30, 2025, respectively[202]. Employee Stock Purchase Plan (ESPP) - The Company adopted the Employee Stock Purchase Plan (ESPP) allowing eligible employees to purchase shares at a discount[206]. - The purchase price under the ESPP cannot be less than 85% of the fair market value on the commencement or purchase date[206]. - Employees can withdraw from the ESPP due to financial hardship with a request made at least 20 business days before the end of the offering period[206]. - The ESPP aims to incentivize employee ownership and engagement within the Company[206].

Core Insights - Biotricity Inc. is set to host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14, 2025, showcasing continued strength in financial performance [1] - The call will feature remarks from the Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, followed by a Q&A session for investors [1] Company Overview - Biotricity is focused on transforming the healthcare market through advanced remote monitoring and chronic care management solutions [3] - The company is recognized for its high standards in preventive and personal care, offering diagnostic and post-diagnostic solutions for chronic conditions [3] - Biotricity develops comprehensive remote health monitoring solutions catering to both medical and consumer markets [3]

Core Insights - Health-E Commerce has partnered with Biotricity to offer the Bioheart remote cardiac monitoring device, making it accessible to over 70 million consumers enrolled in Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs) [1][2][3] Company Overview - Health-E Commerce is the parent brand of FSA Store and HSA Store, focusing on pre-tax health and wellness products, and has been a leader in the direct-to-consumer e-commerce market since 2010 [4] - Biotricity specializes in remote health monitoring solutions, aiming to enhance preventive and personal care for chronic conditions [5] Product Features - Bioheart provides continuous 24/7 monitoring of heart health, capturing data from three different angles to offer a comprehensive view [3] - The device is designed for comfort and can monitor heart activity during various activities, including exercise and sleep, ensuring that subtle changes are not overlooked [3] Market Impact - The collaboration aims to transform healthcare from a reactive to a preventative model, increasing accessibility to high-quality care for millions of individuals [3] - Bioheart joins a growing category of telehealth solutions available through Health-E Commerce, which includes products for weight management, women's health, and mental health [3]

Core Insights - Biotricity Inc. and B-Secur are enhancing their joint cardiac monitoring platform to support ECG data from consumer wearables, transforming the consumer wearables market [1][2][3] - The device-neutral platform launched in early 2025 allows seamless integration of data from various smart devices into Biotricity's cloud-based medical workflow [2][4] - This advancement positions Biotricity and B-Secur as leaders in digital cardiovascular innovation, addressing the growing demand for preventive cardiovascular solutions [3][5] Company Overview - Biotricity aims to make high-quality cardiac care accessible through its collaboration with B-Secur, introducing clinical-grade heart monitoring to consumer wearables [4][7] - B-Secur specializes in advanced biosensing technology, providing medical-grade ECG data for faster diagnosis and management of health conditions [6] - Both companies are focused on bridging the gap between consumer devices and clinical care, enhancing preventive and personal care solutions [4][7] Market Context - Cardiovascular disease accounts for 1 in 3 deaths globally and is projected to triple costs to $1.8 trillion by 2050, highlighting the urgent need for scalable preventive technologies [5] - The integration of consumer wearables into clinical pathways is expected to improve long-term health outcomes while reducing healthcare costs [5]

Company Overview - Biotricity Inc. (BTCY) is part of the Medical sector, which includes 976 individual stocks and currently holds a Zacks Sector Rank of 6, indicating its relative strength among sector groups [2] - Biotricity Inc. has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for BTCY's full-year earnings has increased by 17.9%, reflecting improved analyst sentiment and a stronger earnings outlook [4] - Year-to-date, BTCY has gained approximately 115.6%, significantly outperforming the average loss of 3.3% in the Medical group [4] Industry Comparison - Biotricity Inc. belongs to the Medical Info Systems industry, which consists of 44 companies and currently ranks 51 in the Zacks Industry Rank. This industry has seen a year-to-date gain of about 23.6%, indicating BTCY's strong performance relative to its peers [6] - In contrast, another stock in the Medical sector, Brainsway Ltd. Sponsored ADR (BWAY), has a year-to-date return of 57.5% and belongs to the Medical - Products industry, which ranks 96 and has gained 5.5% year to date [5][6] Investment Consideration - Investors interested in the Medical sector may want to monitor Biotricity Inc. and Brainsway Ltd. Sponsored ADR for their continued strong performance [7]

Core Viewpoint - Biotricity Inc. (BTCY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Business Improvement Indicators - The upgrade in Zacks Rank for Biotricity suggests an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - Over the past three months, the Zacks Consensus Estimate for Biotricity has increased by 17.9%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Biotricity's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].